Mexican women with family history more likely to have triple-negative breast cancer vs. other types
the ONA take:
According to new findings presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in San Antonio, Texas, researchers from the University of California San Diego Moores Cancer Center in La Jolla, California, have found that patients of Mexican descent with breast cancer who had a family history of breast or ovarian cancer were nearly two times as likely to have triple negative breast cancer than other types of breast cancer.
For the study, researchers identified 1,150 women of Mexican descent with breast cancer, 14.9% of whom reported having a first-degree relative with breast or ovarian cancer. They found that women with a first-degree relative who had one of those cancers were nearly twice as likely to be diagnosed with triple-negative breast cancer compared with other types of breast cancer.
The findings suggest that there will be implications in regard to prevention, screening, and treatment of women of Mexican descent with a family history of breast or ovarian cancer. Triple negative breast cancer is often associated with poor outcomes because it lacks the targets for common treatments.
Now, the researchers are investigating whether BRCA mutations are the cause of the association between family history and triple-negative breast cancer that was observed in this study.
Patients of Mexican descent with breast cancer and family history nearly two times as likely to have triple negative breast cancer.
Breast cancer patients of Mexican descent who had a family history of breast or ovarian cancer were almost twice as likely to have triple-negative breast cancer than other subtypes of breast cancer, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 9–12.
"Triple-negative breast cancer is one of the worst breast cancer subtypes in terms of outcomes," said Maria Elena Martinez, PhD, the Sam M. Walton endowed chair for cancer research and a professor in the Department of Family and Preventive Medicine at the University of California San Diego Moores Cancer Center in La Jolla.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|